The proteinic expression of BCL2, BCL-xL, and MCL1 in these LSCs, not only significantly predicts the response to the combination with high sensitivity and specificity, but correlates the combinatorial levels of BCL2 family members with an increased EFS in AML patients as well (58). The gene discussed is MCL1; the disease is acute myeloid leukemia.